Gothenburg, August 28, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company's commercially available platform iTANK, today announced that it has received a Notice of Allowance from the USPTO (United States Patent and Trademark Office) regarding its patent application for the CAR T-cell candidate ELC-401.
The patent application protects Elicera's special antibodies that recognize and bind to the protein IL-13Ra2 (which is often present in large quantities on cancer cells, particularly brain tumors), as well as uses thereof in cancer treatment, such as CAR-T cell therapies.
The patent gives Elicera exclusive rights in U.S. to develop and sell treatments based on these anti-IL-13Ra2 antibodies and related technologies for cancer treatment. This strengthens the company's protection for ELC-401 (its CAR-T cell candidate against glioblastoma) and other future products based on the same principle.
"Securing patent protection for our anti-IL-13Ra2 antibodies, used in CAR T-cell treatments, is commercially very significant because the United States is the world's largest and most valuable market for advanced cell and gene therapies. Exclusive protection there strengthens our ability to develop, partner and commercialize ELC-401 and future products based on the same technology", says Elicera's CEO, Jamal El-Mosleh.